Literature DB >> 18226541

Postoperative exacerbation of chronic obstructive pulmonary disease. Does it exist?

Francesco Leo1, Nicolas Venissac, Daniel Pop, Piergiorgio Solli, Pierluigi Filosso, Antonio Minniti, Davide Radice, Jérôme Mouroux, Lorenzo Spaggiari, Ugo Pastorino, Jacques Jougon, Jean Francois Velly, Alberto Oliaro.   

Abstract

BACKGROUND: One of the characteristics of chronic obstructive pulmonary disease (COPD) is the tendency to develop acute exacerbation, defined by the presence of different clinical findings as worsening dyspnea, increase in sputum purulence and volume. This study was designed to verify if definition of acute COPD exacerbation is applicable to patients who underwent pulmonary surgery, and if it has any impact on postoperative morbidity and mortality.
METHODS: This study was designed to prospectively enrol 1000 patients undergoing pulmonary resection for lung cancer from five different centres. Postoperative exacerbation of COPD was defined by the concomitant presence of three of the following five signs: deteriorating dyspnea, purulent sputum, bronchial secretion volume >10 ml/24 h, fever without apparent cause, and wheezing. The presence of concomitant pulmonary complications excluded the diagnosis of exacerbation, as they may present one or more of these signs.
RESULTS: In the absence of respiratory complications, postoperative stay in exacerbated patients was significantly longer as compared to patients without exacerbation (6.3+/-1.3 vs 8.3+/-1.1, p=0.001). A postoperative exacerbation of COPD was recorded in 276 patients and 152 of them (55%) subsequently developed respiratory complications. Multivariate analysis established that risk factors for postoperative exacerbation are sex (female OR 0.54, CI 0.2-0.8), COPD class (OR 1.5, CI 1.1-8.1), and the postoperative prolonged use of antibiotics (OR 0.6, CI 0.2-0.9).
CONCLUSIONS: Postoperative exacerbation of COPD is an existing, frequent clinical entity after lung resection and, when present, it increases the risk of pulmonary complications. The existing guidelines for the treatment of acute exacerbation should be adapted for the management of patients after lung resection in order to test the hypothesis that they could reduce respiratory morbidity.

Entities:  

Mesh:

Year:  2008        PMID: 18226541     DOI: 10.1016/j.ejcts.2007.11.024

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  Modifiable risk factors for patients undergoing lung cancer surgery and their optimization: a review.

Authors:  Sylvain Gagné; Daniel I McIsaac
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Authors:  Takashi Makino; Hajime Otsuka; Yoshinobu Hata; Satoshi Koezuka; Yoko Azuma; Kazutoshi Isobe; Keishi Sugino; Satoru Ebihara; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2018-03-26

3.  The impact of chronic obstructive pulmonary disease and obesity on length of stay and cost of spine surgery.

Authors:  M Sami Walid; Nadezhda V Zaytseva
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

4.  Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery.

Authors:  A Kamath; D E Stover; A Hemdan; I Belinskaya; R M Steingart; Y Taur; M B Feinstein
Journal:  Lung Cancer Int       Date:  2015-09-01

5.  Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease.

Authors:  Kyoshiro Takegahara; Jitsuo Usuda; Tatsuya Inoue; Takayuki Ibi; Akira Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-03-09

6.  Impact of smoking status and chronic obstructive pulmonary disease on pulmonary complications post lung cancer surgery.

Authors:  Vishnu Jeganathan; Simon Knight; Matthew Bricknell; Anna Ridgers; Raymond Wong; Danny J Brazzale; Warren R Ruehland; Muhammad Aziz Rahman; Tracy L Leong; Christine F McDonald
Journal:  PLoS One       Date:  2022-03-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.